Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641. Published online December 5, 2023
Purpose In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.
Citations
Citations to this article as recorded by
ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock Materials Today Bio.2025; 30: 101424. CrossRef
Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh
Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023
Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.
Citations
Citations to this article as recorded by
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho BJUI Compass.2024; 5(3): 327. CrossRef
Dong Wook Shin, Sang Hyub Lee, Tae-Hwan Kim, Seok Joong Yun, Jong Kil Nam, Seung Hyun Jeon, Seung Chol Park, Seung Il Jung, Jong-Hyock Park, Jinsung Park
Cancer Res Treat. 2019;51(2):556-567. Published online July 16, 2018
Purpose
Health-related quality of life (HRQOL) information related to radical prostatectomy (RP) is valuable for prostate cancer (PC) patients needing to make treatment decisions. We aimed to investigate HRQOL change in PC patients who underwent three types of RP (open, laparoscopic, or robotic) and compared their HRQOL with that of general population.
Materials and Methods
Patients were prospectively recruited between October 2014 and December 2015. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) and PC-specific module (PR25) were administered before surgery (baseline) and at postoperative 3 and 12 months. At each time point, HRQOL was compared, and a difference of 10 out of 0-100 scale was considered clinically significant.
Results
Among 258 screened patients, 209 (41 open, 63 laparoscopic, and 105 robotic surgeries) were included. Compared to baseline, physical, emotional, and cognitive functioning improved at 12 months. Role functioning worsened at 3 months, but recovered to baseline at 12 months. Pain, insomnia, diarrhea, and financial difficulties also significantly improved at 12 months. Most PR25 scales excluding bowel symptoms deteriorated at 3 months. Urinary symptoms and incontinence aid recovered at 12 months, whereas sexual activity and sexual function remained poor at 12 months. Clinically meaningful differences in HRQOL were not observed according to RP modalities. Compared to the general population, physical and role functioning were significantly lower at 3 months, but recovered by 12 months. Social functioning did not recover.
Conclusion
Most HRQOL domains showed recovery within 12 months after RP, excluding sexual functioning and social functioning. Our findings may guide patients considering surgical treatment for PC.
Citations
Citations to this article as recorded by
Quality of life after robotic versus conventional minimally invasive cancer surgery: a systematic review and meta-analysis Russell Seth Martins, Asad Saulat Fatimi, Omar Mahmud, Muhammad Umar Mahar, Arshia Jahangir, Kinza Jawed, Shalni Golani, Ayra Siddiqui, Syed Roohan Aamir, Ali Ahmad Journal of Robotic Surgery.2024;[Epub] CrossRef
The Effect of Discharge Education and Post-Discharge Telephone Counseling on Quality of Life in Patients Undergoing Radical Prostatectomy: A Randomized Controlled Study İpek Köse Tosunöz, Sevgi Deniz Doğan, Şeyma Yurtseven, Sevban Arslan Cukurova Anestezi ve Cerrahi Bilimler Dergisi.2024; 7(3): 205. CrossRef
Health‐related quality of life the first year after a prostate cancer diagnosis a systematic review Louise Dorner Østergaard, Mads Hvid Poulsen, Malene Eiberg Jensen, Lars Lund, Malene Grubbe Hildebrandt, Birgitte Nørgaard International Journal of Urological Nursing.2023; 17(1): 15. CrossRef
Quantitative Analysis of Quality of Life and Exploration of Influencing Factors in Patients Undergoing Radical Prostatectomy Feiyang Wang, Jiajun Chen, Weihao Wang, Mengyao Li, Chao Peng, Shouhua Pan, Chuanchuan Zhan, Keyuan Zhao, Yulei Li, Lulu Zhang, Gang Xu, Jing Jin Urology.2023; 181: 105. CrossRef
Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial Josée Savard, Hanane Moussa, Jean‐François Pelletier, Pierre Julien, Louis Lacombe, Rabi Tiguert, Yves Caumartin, Thierry Dujardin, Paul Toren, Frédéric Pouliot, Michele Lodde, Yves Fradet, Karine Robitaille, Vincent Fradet Cancer Medicine.2023; 12(19): 20163. CrossRef
Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne Cancer Management and Research.2022; Volume 14: 1525. CrossRef
A systematic review of supervised comprehensive functional physiotherapy after radical prostatectomy B. Steenstrup, M. Cartier, F.X. Nouhaud, G. Kerdelhue, M. Gilliaux Progrès en Urologie.2022; 32(7): 525. CrossRef
Perioperative psychological issues and nursing care among patients undergoing minimally invasive surgeries Kehua Yang, Xu Shao, Xinghui Lv, Feimin Yang, Qunyan Shen, Jing Fang, Wei Chen Laparoscopic, Endoscopic and Robotic Surgery.2022; 5(3): 92. CrossRef
A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association Yun-Sok Ha, Kwang Taek Kim, Wook Nam, Hongzoo Park, Sangjun Yoo, Chan Ho Lee, Ho Seok Chung, Woo Suk Choi, Jiyoun Kim, Jaeeun Shin, Jeong Hyun Kim, Cheol Kwak The Korean Journal of Urological Oncology.2022; 20(4): 265. CrossRef
Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study Myung Soo Kim, Seung Il Jung, Ho Seok Chung, Eu Chang Hwang, Dongdeuk Kwon Prostate International.2021; 9(3): 132. CrossRef
Quality of life assessment using EORTC QLQ questionnaires in the prostate cancer population treated with radical prostatectomy: a systematic review Tomasz Jurys, Jacek Durmala Scandinavian Journal of Urology.2021; 55(2): 90. CrossRef
Évaluation de l’observance et de l’adhésion thérapeutique de deux protocoles de rééducation après prostatectomie Benoit Steenstrup, Claire Breton, Guillaume Galliou, François-Xavier Nouhaud Kinésithérapie, la Revue.2021; 21(234): 12. CrossRef
Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy Yann Neuzillet, Mathieu Rouanne, Jean-François Dreyfus, Jean-Pierre Raynaud, Marc Schneider, Morgan Roupret, Sarah Drouin, Marc Galiano, Xavier Cathelinau, Thierry Lebret, Henry Botto Asian Journal of Andrology.2021; 23(4): 370. CrossRef
The Effect of Post-prostatectomy Urinary Incontinence on Health-related Quality of Life in Patients with Prostate Cancer Jeong Hyun Kim, Yeon Soo Jang, Young Deuk Choi, Eui Geum Oh Korean Journal of Adult Nursing.2019; 31(3): 293. CrossRef
Prostate-specific health-related quality of life and patient-physician communication — A 3.5-year follow-up Nicole Ernstmann, Jan Herden, Lothar Weissbach, André Karger, Kira Hower, Lena Ansmann Patient Education and Counseling.2019; 102(11): 2114. CrossRef